Eli Lilly broke ground Monday on a $6.5 billion manufacturing facility in Houston’s Generation Park, a project Texas Gov. Greg Abbott called the largest active pharmaceutical ingredient investment in state history. The 600-plus jobs it’s expected to create matter to the Houston area directly. But the more immediate relevance for readers everywhere may be what the plant will actually produce: Foundayo, Lilly’s newly approved oral GLP-1 pill, along with other small-molecule medicines and advanced therapeutics.
The facility is Lilly’s fifth domestic active pharmaceutical ingredient production site announced since 2020, part of a broader $50 billion commitment the company has made to expand U.S.-based manufacturing. “This $6.5 billion Eli Lilly investment in Houston is the largest active pharmaceutical ingredient project in Texas history and will create more than 600 high-wage jobs, right here in Texas,” Abbott said in a statement. Alongside the groundbreaking, Lilly announced $12.5 million to build a workforce training pipeline with nearby San Jacinto College, plus a separate $2.5 million donation to the college’s foundation for student scholarships. “This facility will run on the talent of this community, powered by our relationship with San Jacinto College,” said Edgardo Hernandez, Lilly’s manufacturing operations president. “We’re hiring across the greater Houston area to help residents build careers close to home.”
Generation Park itself has spent 13 years positioning for exactly this kind of investment. McCord Development, the master developer of the 4,300-acre site, lost out on Amgen’s $550 million biomanufacturing project in 2021 and responded by expanding its life sciences workforce training partnerships. That bet is paying off twice over: Bristol Myers Squibb separately announced in August that it would build a $2.3 billion, 600,000-square-foot manufacturing campus at the same development…